Drugs / anti-MART-1 F5 TCR PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00923195 | Dec 2008 → Aug 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-MART-1 F5 TCR PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923195 ↗ |
| Action | Deplete | “gp100:154-162 TCR or MART-1:27-35 TCR transduced T-cells could efficiently kill HLAA\*0201 positive tumors.” NCT00923195 ↗ |
| Modality | Cell therapy | “These gp100 and MART-1 TCR transduced cells will be separately expanded and tested for their anti-tumor activity.” NCT00923195 ↗ |
| Route | Intravenous | “infusion will be administered intravenously over 20 to 30 minutes” NCT00923195 ↗ |